



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 	ATTY. DOCKET NO. 208.3 A2	APPLICATION NO. 09/675,323
	APPLICANT HENRY LARDY, et al.	
	FILING DATE September 28, 2000	GROUP 1623

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		5,641,766	6/24/97	Lardy			
		6,372,732 A1	4/16/02	Lardy			12/4/00
		5,292,730	3/8/94	Lardy			
		5,807,848	9/15/98	Lardy			
		5,424,463	6/13/95	Lardy et al			
		5,707,983	1/13/98	Lardy			
		5,585,371	12/17/96	Lardy			
		6,423,698	7/23/02	Labrie			6/7/95
		5,744,462	4/28/98	Schwartz et al			
		4,684,635	8/4/87	Orentreich et al			
		5,204,337	4/20/93	Labrie et al			
		4,898,694	2/6/90	Schwartz et al			
		5,028,631	7/2/91	Schwartz et al			
		5,001,119	3/19/91	Schwartz et al			
		4,213,978	7/22/80	Bodor et al			
		5,817,649	10/6/98	Labrie			
		4,598,072	7/1/86	Schweikert et al			
		4,757,061	7/12/88	Faustini et al			
		5,017,568	5/21/91	Holt et al			
		5,763,433	6/9/98	Morfin			
		6,740,646	5/25/04	Roberts			
		5,527,789	6/18/96	Nyce			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
208.3 A2

APPLICATION NO.
09/675,323

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT
HENRY LARDY, et al.

FILING DATE
September 28, 2000

GROUP
1623

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL	PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	20040043973 A1	Ahlem et al			
	20030113284 A1	Dalko et al			
	20040116359 A1	Ahlem et al			
	20040024231 A1	Ring et al			
	20040138187 A1	Ahlem et al			
	20020187973 A1	Labrie			
	20030060425 A1	Ahlem et al			
	20040097406 A1	Ahlem et al			
	20040157812 A1	Labrie et al			
	20030083231 A1	Ahlem et al			
	20040082556 A1	Labrie et al			


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 95/10527	4/20/95	PCT				
	EP 0 133 995 B1	4/15/92	Europe				

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 208.3 A2	APPLICATION NO. 09/675,323
	APPLICANT HENRY LARDY, et al.	
	FILING DATE September 28, 2000	GROUP 1623

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, ETC.).
	Miyamoto, et al., 3 β -Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity, <i>Proc. Natl. Acad. Sci. USA</i> , 100:4440-4444, 2003
	Miyamoto, et al., Δ^5 -androstenediol is a natural hormone with androgenic activity in human prostate cancer cells, <i>Proc. Natl. Acad. Sci. U. S. A.</i> 95(19):11083-11088, 1998
	Tan et al., Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells, <i>Mol. Endocrinol.</i> 11(4):450-459, 1997
	Taplin, et al., Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist, <i>Cancer Research</i> , 59:2511-2515, 1999
	Rao, et al., Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone, <i>Cancer Res.</i> 59(13):3084-3089, 1999
	Onizuka, et al., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody, <i>Cancer Res.</i> 59(13):3128-3133, 1999
	Toes, et al., CD4 T cells and their role in antitumor immune responses, <i>J. Exp. Med.</i> 1999 Mar 1;189(5):753-756, 1999
	Weber, et al., Tumor immunity and autoimmunity induced by immunization with homologous DNA, <i>J. Clin. Invest.</i> 102(6):1258-1264, 1998
	Horiguchi, et al., Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells, <i>Cancer Res.</i> 1999 Jun 15;59(12):2950-6, 1999
	Segaloff, A., et al., "Hormonal therapy in cancer of the breast II. Effect of methylandrostenediol on clinical course and hormonal excretion", <i>Cancer</i> , Vol. 5(2), pp.271-74 (1952)
	Segaloff, A., et al., "Hormonal therapy in cancer of the breast IV. Effect of androstenediol on clinical course and hormonal excretion", <i>Cancer</i> , Vol. 5(6), pp.271-74 (1952)
	Comley, J., et al., "Antipneumocystis activity of 17C91, a prodrug of Atovaquone", <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 39 (10), pp. 2217-19 (1995)
	Kurimoto, A., et al., "Prodrugs of 9-benzyl-8-hydroxy-2-(2-hydroxyethylthio) adenine: Potent interferon inducing agents in monkeys", <i>Chem Pharm Bull</i> , pp. 466-69 Vol. 52(4) (2004)
	Weiss, W., et al., "In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuran-1 β -methylcarbapenems", <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 43(3), pp. 460-64 (1999)
	Zhao, Z, et al., "Mechanism, structure-activity studies, and potential applications of glutathione S-transferase-catalyzed cleavage of sulfonamides", <i>Drug Metabolism and Disposition</i> , Vol. 27(9), pp. 992-98 (1999)
	Li., et al., "Mechanism of intestinal absorption of an orally active β -lactam prodrug: uptake and transport of carindacillin in caco-2 cells", <i>J Pharmacology and Experimental Therapeutics</i> , Vol 290(3), pp. 958-64 (1999)
	Choi W., et al., "Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-YL0 purine, and oral prodrug for the antiviral agent penciclovir", <i>Drug Metabolism and Disposition</i> , Vol. 29(7), pp. 945-49 (2001)
	Weisz, I, et al., "Selective reactions of some steroids with diethyl dicarbonate", <i>Arch Pharm</i> , Vol 319(10), pp. 952-3 (1986)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	